Schering results miss targets
77782
Schering-Plough Corp  on Monday reported third-quarter profit and sales that fell short of Wall Street's target, sending shares down more than 10 percent amid concerns about its flagship cholesterol drugs.
434669
German chemical and drug maker Bayer AG and New Jersey pharmaceutical company Schering-Plough Corp. announced an alliance Monday under which Schering-Plough will distribute Bayer's primary care pharmaceutical products in the United States.
575659
Forest Laboratories Inc. (FRX) on Tuesday said its experimental hypertension drug failed to meet all its goals in an effectiveness study, an outcome that will delay development and may lead to a new trial.
442828
Schering's hepatitis C drug works as well as Roche's.
370237
Schering-Plough's positive study results send shares of Vertex down.
754804
The maker of analog microchips said Tuesday its  fourth-quarter revenue would miss earlier targets because of  weak demand from computing and communications equipment makers.
608420
Novartis AG lowered its full-year  results outlook as generic competition pressured sales of a key  blood-pressure drug, and said U.S. regulators had delayed the  approval process for an important cancer treatment.
549877
The drug maker Schering-Plough Corporation said yesterday that its fourth-quarter profit surged 75 percent as strong sales of its cholesterol, arthritis and allergy medicines helped offset rising research and marketing spending.
95723
Drug maker Schering-Plough Corp  on Tuesday reported a fourth-quarter loss as special charges from its acquisition of Organon Biosciences late last year offset sharply higher sales.
594500
Schering-Plough Corp. SGP.N on  Thursday reported a quarterly profit after a year-ago loss, as  positive foreign exchange trends helped offset poor sales of  its allergy and hepatitis drugs.
414190
FRANKFURT/CHICAGO  - U.S. regulators have demanded  more clinical studies of a new substance designed to produce  clearer MRI pictures of clogged arteries, Germany's Schering AG  and U.S. partner Epix Pharmaceuticals Inc. said on Friday.
205867
German drug maker Schering, recently acquired by pharmaceuticals and chemicals giant Bayer, has said that it was teaming up with British drug giant AstraZeneca to develop a new treatment against breast cancer.
227799
Drugmakers Merck & Co.  and Schering-Plough Corp.  reported second-quarter results that handily topped Wall Street expectations on Monday, helped by increased sales of the cholesterol-lowering drugs they co-market and other medicines.
677326
BASEL, Switzerland  - Swiss drugmaker Novartis AG  missed forecasts with a 42 percent drop in fourth-quarter net profit, hit by generic competition and a one-off restructuring charge, sending its shares lower.
730824
Charges hurt the quarterly results of Johnson & Johnson, Merck & Co. and Schering-Plough Corp., but the drugmakers' shares rose as J&J's earnings beat Wall Street forecasts and Merck sales edged higher despite the withdrawal of its best-selling Vioxx arthritis drug.
757229
Genzyme Corp. of Cambridge and German partner Bayer Schering Pharma AG said they have begun phase 3 trials of their cancer drug Campath to treat multiple sclerosis. The companies said they plan on reporting phase 2 results Oct. 14. After phase 3, they hope to seek US regulatory approval in 2011 to market the drug, also known as alemtuzumab, to ...
318406
Germany&#039;s Bayer AG  fell  short of the 95 percent stake it needs to start a squeeze out  of minority shareholders in drugmaker Schering AG, but still  plans to buy the rest of the shares, it said on Wednesday.